Integra LifeSciences (NASDAQ:IART) Updates Q2 Earnings Guidance

Integra LifeSciences (NASDAQ:IART) updated its second quarter earnings guidance on Monday. The company provided EPS guidance of $0.60-0.65 for the period, compared to the consensus EPS estimate of $0.74. The company issued revenue guidance of $411-416 million, compared to the consensus revenue estimate of $395.81 million. Integra LifeSciences also updated its FY 2024 guidance to 3.010-3.110 EPS.

Analyst Ratings Changes

A number of research analysts have recently commented on the stock. Truist Financial dropped their price objective on shares of Integra LifeSciences from $37.00 to $25.00 and set a hold rating for the company in a research note on Tuesday. Citigroup raised shares of Integra LifeSciences from a sell rating to a neutral rating and set a $38.00 price target for the company in a research report on Wednesday, April 3rd. Bank of America decreased their price target on shares of Integra LifeSciences from $42.00 to $26.00 and set an underperform rating on the stock in a report on Tuesday. Wells Fargo & Company downgraded Integra LifeSciences from an overweight rating to an equal weight rating and dropped their price objective for the stock from $45.00 to $25.00 in a report on Tuesday. Finally, StockNews.com cut Integra LifeSciences from a buy rating to a hold rating in a report on Tuesday, April 30th. Three research analysts have rated the stock with a sell rating, six have given a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of Hold and a consensus target price of $36.80.

Integra LifeSciences Stock Down 0.7 %

Integra LifeSciences stock traded down $0.17 during midday trading on Wednesday, hitting $24.91. 1,907,390 shares of the company were exchanged, compared to its average volume of 823,586. The company has a market cap of $1.96 billion, a PE ratio of 30.22, a price-to-earnings-growth ratio of 0.87 and a beta of 1.17. Integra LifeSciences has a fifty-two week low of $22.36 and a fifty-two week high of $50.78. The company’s fifty day moving average price is $32.95 and its 200-day moving average price is $38.24. The company has a debt-to-equity ratio of 0.94, a current ratio of 3.45 and a quick ratio of 2.18.

Integra LifeSciences (NASDAQ:IART) last posted its earnings results on Monday, May 6th. The life sciences company reported $0.55 EPS for the quarter, hitting analysts’ consensus estimates of $0.55. The business had revenue of $368.90 million for the quarter, compared to analysts’ expectations of $361.96 million. Integra LifeSciences had a net margin of 4.39% and a return on equity of 15.19%. The business’s revenue for the quarter was down 3.2% compared to the same quarter last year. During the same period in the previous year, the company posted $0.74 earnings per share. On average, research analysts predict that Integra LifeSciences will post 3.19 EPS for the current fiscal year.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.